Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute on Drug Abuse (NIDA) |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00000338 |
The purpose of this study is to evaluate clinical safety issues pertaining to lisuride, to cocaine, and to its interaction in a chronic, crack dependent population, and to determine how pretreatment with lisuride modifies the subjective as well as physiological effects of cocaine.
Condition | Intervention | Phase |
---|---|---|
Cocaine-Related Disorders |
Drug: Lisuride |
Phase I |
Study Type: | Interventional |
Study Design: | Treatment, Open Label |
Official Title: | Infusion Laboratory: Protocol 2 (Lisuride) |
Estimated Enrollment: | 2 |
Study Start Date: | March 1996 |
Ages Eligible for Study: | 21 Years to 50 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
M/F ages 21-50. Meet DSM-IV criteria for cocaine dependence. Agree to conditions of the study and sign informed consent.
Exclusion Criteria:
Psychiatric disorder that requires medication therapy. History of seizures. Pregnant and/or nuring women. Dependence on ETOH or benzodiazepines or other sedative/hypnotics. Acute hepatitis. Other medical condtions that deem participation to be unsafe.
United States, California | |
Friends Research Institute | |
Los Angeles, California, United States, 90025 |
Principal Investigator: | Walter Ling, M.D. | Friends Research Institute, Inc. |
Study ID Numbers: | NIDA-3-0010-3, Y01-3-0010-3 |
Study First Received: | September 20, 1999 |
Last Updated: | August 16, 2005 |
ClinicalTrials.gov Identifier: | NCT00000338 |
Health Authority: | United States: Federal Government |
Cocaine-Related Disorders Dopamine Mental Disorders Substance-Related Disorders |
Disorders of Environmental Origin Lisuride Serotonin |
Serotonin Agonists Neurotransmitter Agents Serotonin Agents Molecular Mechanisms of Pharmacological Action Anti-Dyskinesia Agents Therapeutic Uses |
Physiological Effects of Drugs Antiparkinson Agents Dopamine Agents Dopamine Agonists Central Nervous System Agents Pharmacologic Actions |